Related Experiment Video
Updated: Sep 28, 2026
Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration
Published on: April 27, 2018
Targeting of adenoviral vectors for gene therapy of prostate cancer
1Department of Urology, Erasmus University and Academic Hospital, Rotterdam, The Netherlands.
Abstract:
The transduction of cytotoxic genes by adenoviral vectors into prostatic cells offers a new entity for the treatment of prostate cancer. Current adenoviral vectors cannot infect prostatic cells selectively, and expression of therapeutic genes is often too low to be efficient. Bispecific antibodies may alter the natural tropism of adenoviral vectors towards prostatic cells, and increase the efficacy of infection (transductional targeting). The transcription of transgenes can be placed under the control of prostate-specific promoters (transcriptional targeting), and the combination of this with transductional targeting may be warranted to construct targeted vectors that are adequate for gene therapy of the prostate. Prostate Cancer and Prostatic Diseases (2000) 3, 308-312
Insights
Targeted adenoviral vectors show promise for prostate cancer gene therapy. Combining bispecific antibodies for cell targeting and prostate-specific promoters enhances gene delivery and expression for improved treatment efficacy.
Area of Science:
- Oncolytic virotherapy
- Gene therapy for prostate cancer
Background:
- Adenoviral vectors are being explored for delivering cytotoxic genes to treat prostate cancer.
- Current adenoviral vectors lack selectivity for prostatic cells, leading to inefficient gene expression.
Purpose of the Study:
- To investigate methods for enhancing adenoviral vector targeting and gene expression in prostatic cells for improved prostate cancer gene therapy.
- To explore the potential of combining transductional and transcriptional targeting strategies.
Main Methods:
- Utilizing bispecific antibodies to redirect adenoviral vector tropism towards prostatic cells (transductional targeting).
- Employing prostate-specific promoters to control transgene transcription (transcriptional targeting).
Main Results:
- Bispecific antibodies can potentially enhance adenoviral vector infection of prostatic cells.
- Combining transductional and transcriptional targeting may lead to more effective gene therapy vectors.
Conclusions:
- Targeted adenoviral vectors, through combined strategies, hold promise for advancing prostate cancer gene therapy.
- Further development is warranted to create effective targeted vectors for prostate cancer treatment.
